Expression ofp16INK4A and alterations of the 9p21-23 chromosome region in non-small-cell lung carcinomas: Relationship with tumor growth parameters and ploidy status
- 20 March 2000
- journal article
- Published by Wiley in International Journal of Cancer
- Vol. 89 (2) , 133-141
- https://doi.org/10.1002/(sici)1097-0215(20000320)89:2<133::aid-ijc6>3.0.co;2-c
Abstract
The 9p21‐23 chromosome region harbors a number of known and putative tumor‐suppressor genes (TSGs). The best characterized gene in this area is p16INK4A (CDKN2A). Alterations of its product have been observed in various malignancies, including non‐small‐cell lung carcinomas (NSCLCs). We earlier investigated the mechanisms underlying p16INK4A inactivation. In the present study, we examined, in a series of 87 NSCLCs, its relationship with the kinetic parameters [proliferation index (PI) and apoptotic index (Al)] and the ploidy status of the tumors. In addition, we extended our previous LOH analysis of the 9p21‐23 region by examining flanking areas of p16INK4A. Aberrant p16 expression was observed in 41.4% of the carcinomas. A significant association was found with increased PI (p = 0.037), but not with apoptosis. Aneuploid tumors were more frequently correlated with abnormal p16 staining (p = 0.05). A high frequency of allelic imbalance (Alm) was noticed at the D9S161 (51.3%) and D9S157 (64.5%) loci, which lie approximately 4cM centromeric and 7cM telomeric, respectively, to CDKN2A. Abnormal p16INK4A expression was strongly correlated with Alm at D9S161 (p = 0.004). Allelic losses at D9S157 occurred more frequently in early stages (p = 0.018) and were significantly associated with deletions at D9S161 (p = 0.035). We conclude that, in a sub‐set of NSCLCs, (i) abnormal p16 expression contributes to tumor growth mainly by increasing the proliferative activity in the initial stages of carcinogenesis; (ii) the association with aneuploidy merely reflects the impact of aberrant p16 on proliferative activity; and (iii) other putative TSGs possibly reside within the 9p21‐23 region that possibly co‐operate in certain cases with CDKN2A in the development of NSCLCs. Int. J. Cancer (Pred. Oncol.) 89:133–141, 2000.Keywords
This publication has 23 references indexed in Scilit:
- In squamous cell carcinoma of the vulva, overexpression of p53 is a late event and neither p53 nor mdm2 expression is a useful marker to predict lymph node metastasesBritish Journal of Cancer, 1999
- Alterations of the p16-pRb Pathway and the Chromosome Locus 9p21–22 in Non-Small-Cell Lung CarcinomasThe American Journal of Pathology, 1998
- Human bladder cancers and normal bladder mucosa present the same hot spot of heterozygous chromosome-9 deletionInternational Journal of Cancer, 1998
- Histopathologic and Molecular Alterations in Bronchial Epithelium in Habitual Smokers of Marijuana, Cocaine, and/or TobaccoJNCI Journal of the National Cancer Institute, 1998
- Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancerLung Cancer, 1998
- Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cellsOncogene, 1998
- DNA Aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in non-small-cell lung carcinomaVirchows Archiv, 1997
- Differential Inactivation of CDKN2 and Rb Protein in Non--Small-Cell and Small-Cell Lung Cancer Cell LinesJNCI Journal of the National Cancer Institute, 1995
- Proliferating cell nuclear antigen and Ki-67 in lung carcinoma. Correlation with DNA flow cytometric analysisCancer, 1994
- Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.The Journal of cell biology, 1992